A Study of BGB-11417 in Participants With Myeloid Malignancies

Key Inclusion Criteria:

Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:

1. AML, nonacute promyelocytic leukemia
2. MDS
3. MDS/MPN
4. Eastern Cooperative Oncology Group performance status of 0 to 2.

Adequate organ function defined as:

1. Creatinine clearance ≥ 50 milliliters/minute (mL/min) (or between 30 and 49 mL/min in unfit AML cohort)
2. Adequate liver function
3. Life expectancy of > 12 weeks.
4. Ability to comply with the requirements of the study.

Key Exclusion Criteria:

1. A diagnosis of acute promyelocytic leukemia.
2. Prior malignancy within the past 2 years, except for curatively treated localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer.
3. Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
4. Prior therapy with a B-cell lymphoma-2 inhibitor or azacitidine except for participants who meet HMA-failure criteria
5. Known central nervous system involvement by leukemia.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.